corp_html/html/Pipeline-2.htm


<p><b>NCE's in Development Phase</b></p>
<p><b>PLD-116</b></p>
<p>Approval of the German authorities was obtained to conduct the PLD-116 Phase 
  I clinical study in Germany in December 2000. Prior to that, all the activities 
  necessary to fulfill the requirements for the clinical testing of the compound 
  had been undertaken and the pre-clinical testing completed. The PLD-116 project 
  team has been established in December 1999, to develop peptide PL-10.1 into 
  a drug for the treatment of inflammatory bowel disease. The peptide is derived 
  from a natural protein and provides a novel anti-inflammatory treatment option 
  for inflammatory bowel disease.</p>
<p><b>PLD-117</b></p>
<p>The peptide PLD-117 for the treatment of thrombocytopenia, a severe complication 
  of cancer chemotherapy, was brought to clinical study trials in the USA in December 
  2000. The proposed treatment is based on a unique approach using peptide that 
  activates thrombopoietin (TPO) receptor. Prior to favourable communication from 
  the FDA regarding the IND filling, and the evaluation of the clinical protocol, 
  PLIVA has signed a licensing agreement with Receptron, Inc., a Californian based 
  Biotech Company, and acquired exclusive rights to develop and market this possible 
  new drug.</p>
<p><b>PLD-118</b></p>
<p>The licensed in novel antifungal agent PLD-118 was successfully brought into 
  clinical development ahead of schedule in November 2000. PLD-118 has the potential 
  to be the first novel oral antifungal for the treatment of Candida infections 
  since the introduction of azoles in the 80's. After completing the preclinical 
  package and successful review of necessary documents by the ethics committee 
  in Germany, clinical studies started in November.</p>
1	dpavlin	1.2
2			<p><b>NCE's in Development Phase</b></p>
3	dpavlin	1.1	<p><b>PLD-116</b></p>
4			<p>Approval of the German authorities was obtained to conduct the PLD-116 Phase
5			I clinical study in Germany in December 2000. Prior to that, all the activities
6			necessary to fulfill the requirements for the clinical testing of the compound
7			had been undertaken and the pre-clinical testing completed. The PLD-116 project
8			team has been established in December 1999, to develop peptide PL-10.1 into
9	dpavlin	1.2	a drug for the treatment of inflammatory bowel disease. The peptide is derived
10			from a natural protein and provides a novel anti-inflammatory treatment option
11			for inflammatory bowel disease.</p>
12	dpavlin	1.1	<p><b>PLD-117</b></p>
13			<p>The peptide PLD-117 for the treatment of thrombocytopenia, a severe complication
14			of cancer chemotherapy, was brought to clinical study trials in the USA in December
15			2000. The proposed treatment is based on a unique approach using peptide that
16			activates thrombopoietin (TPO) receptor. Prior to favourable communication from
17			the FDA regarding the IND filling, and the evaluation of the clinical protocol,
18			PLIVA has signed a licensing agreement with Receptron, Inc., a Californian based
19			Biotech Company, and acquired exclusive rights to develop and market this possible
20			new drug.</p>
21			<p><b>PLD-118</b></p>
22			<p>The licensed in novel antifungal agent PLD-118 was successfully brought into
23			clinical development ahead of schedule in November 2000. PLD-118 has the potential
24			to be the first novel oral antifungal for the treatment of Candida infections
25			since the introduction of azoles in the 80's. After completing the preclinical
26			package and successful review of necessary documents by the ethics committee
27	dpavlin	1.2	in Germany, clinical studies started in November.</p>